Advertisement
Advertisement
SPRY
ARS Pharmaceuticals, Inc. Common Stock
8.74
USDSponsored
-0.26
-2.89%
May 08, 16:00 UTC -4
Closed
Pre-Market
8.71
-0.03
-0.34%
SPRY Earnings Reports
Positive Surprise Ratio
SPRY beat 11 of 21 last estimates.
52%
Next Report
In 4 Days
Date of Next Report
May 15, 2026
Estimate for Q1 26 (Revenue/ EPS)
$22.75M
/-$0.51
Implied change from Q4 25 (Revenue/ EPS)
-18.99%
/+21.43%
Implied change from Q1 25 (Revenue/ EPS)
+185.38%
/+45.71%
ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Mar 09, 2026, SPRY reported earnings of -0.42 USD per share (EPS) for Q4 25, beating the estimate of -0.45 USD, resulting in a 6.77% surprise. Revenue reached 28.09 million, compared to an expected 26.10 million, with a 7.63% difference. The market reacted with a -0.11% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.51 USD, with revenue projected to reach 22.75 million USD, implying an increase of 21.43% EPS, and decrease of -18.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were ARS Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.42, beating estimates by 6.77%, and revenue of $28.09M, 7.63% above expectations.
How did the market react to ARS Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -0.11%, changed from $9.06 before the earnings release to $9.05 the day after.
When is ARS Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 15, 2026.
What are the forecasts for ARS Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 6
analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.51 and revenue of $22.75M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement